Patents Assigned to Besins Healthcare Luxembourg SARL
-
Patent number: 11040043Abstract: The present invention provides compositions and methods for providing sustained release of an active agent through the skin of a subject, wherein a pharmaceutical percutaneous composition comprises at least one fatty acid ester and a therapeutically effective amount of active agent.Type: GrantFiled: August 23, 2018Date of Patent: June 22, 2021Assignee: BESINS HEALTHCARE LUXEMBOURG SARLInventors: Valerie Masini-Eteve, Denis Canet
-
Patent number: 10918601Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally aministering the compositions, such as intranasally or intravaginally.Type: GrantFiled: June 25, 2020Date of Patent: February 16, 2021Assignee: BESINS HEALTHCARE LUXEMBOURG SARLInventors: Maynard Emanuel Lichty, Garry T. Gwozdz
-
Publication number: 20200390706Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.Type: ApplicationFiled: June 25, 2020Publication date: December 17, 2020Applicant: Besins Healthcare Luxembourg SARLInventors: Maynard Emanuel Lichty, Garry T. Gwozdz
-
Patent number: 10695295Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.Type: GrantFiled: March 3, 2014Date of Patent: June 30, 2020Assignee: BESINS HEALTHCARE LUXEMBOURG SARLInventors: Maynard Emanuel Lichty, Garry T. Gwozdz
-
Publication number: 20190380948Abstract: The present invention relates to transdermal pharmaceutical compositions such as gels containing a SERM selected from the group consisting of endoxifen, droloxifene, clomifene, raloxifene, tamoxifen, 4-OH tamoxifen, toremifene, danazol and the pharmaceutically acceptable salts thereof, and to methods of making and using the same.Type: ApplicationFiled: January 14, 2019Publication date: December 19, 2019Applicant: BESINS HEALTHCARE LUXEMBOURG SARLInventor: Valérie MASINI-ETEVE
-
Publication number: 20190160077Abstract: The present invention provides compositions and methods for providing sustained release of an active agent through the skin of a subject, wherein a pharmaceutical percutaneous composition comprises at least one fatty acid ester and a therapeutically effective amount of active agent.Type: ApplicationFiled: August 23, 2018Publication date: May 30, 2019Applicant: Besins Healthcare Luxembourg SARLInventors: Valerie MASINI-ETEVE, Denis CANET
-
Patent number: 10080760Abstract: The present invention provides compositions and methods for providing sustained release of an active agent through the skin of a subject, wherein a pharmaceutical percutaneous composition comprises at least one fatty acid ester and a therapeutically effective amount of active agent.Type: GrantFiled: October 26, 2010Date of Patent: September 25, 2018Assignee: BESINS HEALTHCARE LUXEMBOURG SARLInventors: Valerie Masini-Eteve, Denis Canet
-
Patent number: 9675698Abstract: The present invention relates to a pharmaceutical composition in the form of a hydro-alcoholic gel or a solution for transdermal application, comprising: from about 0.2% to about 1.5% of dihydrotestosterone; and from about 0.2 to about 3% of isopropyl myristate.Type: GrantFiled: October 11, 2011Date of Patent: June 13, 2017Assignee: BESINS HEALTHCARE LUXEMBOURG SARLInventors: Valerie Masini-Eteve, Brigitte Taravella
-
Patent number: 9572818Abstract: Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.Type: GrantFiled: June 12, 2013Date of Patent: February 21, 2017Assignee: BESINS HEALTHCARE LUXEMBOURG SARLInventors: Georg Achleitner, Eva-Maria Hoiser, Laura Pickersgill
-
Patent number: 9504697Abstract: Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings.Type: GrantFiled: May 15, 2015Date of Patent: November 29, 2016Assignee: BESINS HEALTHCARE LUXEMBOURG SARLInventors: Anne Caufriez, Georges Copinschi
-
Publication number: 20150320767Abstract: Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings.Type: ApplicationFiled: May 15, 2015Publication date: November 12, 2015Applicant: BESINS Healthcare Luxembourg SARLInventors: Anne Caufriez, Georges Copinschi
-
Patent number: 9084797Abstract: Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings.Type: GrantFiled: May 11, 2012Date of Patent: July 21, 2015Assignee: BESINS HEALTHCARE LUXEMBOURG SARLInventors: Anne Caufriez, Georges Copinschi
-
Publication number: 20140335133Abstract: Described are sterile, ready-to-use, pharmaceutical oil-in-water emulsion compositions for parenteral administration comprising: 0.015 to 0.5% wt/vol progesterone; 0.5 to 10% wt/vol oil, wherein the oil comprises at least 85% wt./wt. triglyceride; 0.0425 to 4.1% wt/vol phospholipid; 80-99.4% wt/vol aqueous medium; wherein the composition has an osmolality in the range of 200-1000 mOsm/kg. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.Type: ApplicationFiled: May 16, 2014Publication date: November 13, 2014Applicant: BESINS Healthcare Luxembourg SARLInventors: Georg Achleitner, Eva-Maria Hoiser, Laura Pickersgill
-
Publication number: 20140329788Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 31, 2014Publication date: November 6, 2014Applicants: Besins Healthcare Luxembourg SARL, Unimed Pharmaceuticals, LLCInventors: Ramana Malladi, Jodi Stahlman
-
Publication number: 20140248367Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.Type: ApplicationFiled: March 3, 2014Publication date: September 4, 2014Applicant: Besins Healthcare Luxembourg SARLInventors: Maynard Emanuel Lichty, Garry T. Gwozdz
-
Patent number: 8765149Abstract: Described are sterile, ready-to-use, pharmaceutical oil-in-water emulsion compositions for parenteral administration comprising: 0.015 to 0.5% wt/vol progesterone; 0.5 to 10% wt/vol oil, wherein the oil comprises at least 85% wt./wt. triglyceride; 0.0425 to 4.1% wt/vol phospholipid; 80-99.4% wt/vol aqueous medium; wherein the composition has an osmolality in the range of 200-1000 mOsm/kg. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.Type: GrantFiled: April 25, 2011Date of Patent: July 1, 2014Assignee: Besins Healthcare Luxembourg SarlInventors: Georg Achleitner, Eva-Maria Hoiser, Laura Pickersgill
-
Patent number: 8759329Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 24, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 8754070Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 17, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 8741881Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 3, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg, SARLInventors: Ramana Malladi, Jodi Stahlman
-
Publication number: 20140147474Abstract: Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.Type: ApplicationFiled: June 12, 2013Publication date: May 29, 2014Applicant: BESINS Healthcare Luxembourg SARLInventors: Georg Achleitner, Eva-Maria Hoiser, Laura Pickersgill